Cyclacel Pharmaceuticals Inc. Stock
With 12 Sell predictions and only 2 Buy predictions the community sentiment for Cyclacel Pharmaceuticals Inc. is rather negative.
On the other hand, the target price of 14 € is above the current price of 0.22 € for Cyclacel Pharmaceuticals Inc., so the potential is actually 6263.64%.
Our community identified positive and negative aspects for Cyclacel Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "EBIT Margin" as a plus for the Cyclacel Pharmaceuticals Inc. stock. On the other hand our users think that "Expected Cash Flow" could be a problem in the future.
Pros and Cons of Cyclacel Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cyclacel Pharmaceuticals Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Cyclacel Pharmaceuticals Inc. | - | - | - | - | - | - | - |
Vaxart Inc. | 0.400% | -4.511% | 10.998% | -34.983% | 47.789% | -87.351% | - |
Larimar Therapeutics Inc. | - | 0.781% | -6.522% | 84.286% | 58.088% | -0.769% | -67.305% |
aTyr Pharma Inc | 4.610% | -2.454% | 10.417% | -26.389% | 23.256% | -57.258% | -69.795% |
Comments
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) had its price target lowered by analysts at Roth Mkm from $21.00 to $11.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat